Oronsky, B., Reid, T. R., Oronsky, A., & Carter, C. A. (2017). What’s new in SCLC? A review. Neoplasia., 19(10), 842–847. https://doi.org/10.1016/j.neo.2017.07.007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hou, J. M., Krebs, M. G., Lancashire, L., et al. (2012). Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. Journal of Clinical Oncology, 30(5), 525–532. https://doi.org/10.1200/JCO.2010.33.3716

Article  PubMed  Google Scholar 

Torres-Durán, M., Curiel-García, M. T., Ruano-Ravina, A., et al. (2021). Small-cell lung cancer in never-smokers. ESMO Open., 6(2), 100059. https://doi.org/10.1016/j.esmoop.2021.100059

Article  PubMed  PubMed Central  Google Scholar 

Oronsky, B., Abrouk, N., Caroen, S., Lybeck, M., Guo, X., Wang, X., Yu, Z., & Reid, T. (2022). A 2022 update on extensive stage small-cell lung cancer (SCLC). Journal of Cancer, 13(9), 2945–2953. https://doi.org/10.7150/jca.75622

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganti, A. K. P., Loo, B. W., Bassetti, M., et al. (2021). Small cell lung cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19(12), 1441–1464. https://doi.org/10.6004/jnccn.2021.0058

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gergen, A. K., Scott, C. D., & Mitchell, J. D. (2020). Surgery for limited stage small cell lung cancer. Journal of Thoracic Disease, 12(10), 6291–6297. https://doi.org/10.21037/jtd.2020.03.79

Article  PubMed  PubMed Central  Google Scholar 

Blackhall, F., Girard, N., Livartowski, A., et al. (2023). Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: A retrospective cohort study. British Medical Journal Open, 13(2), e052556. https://doi.org/10.1136/bmjopen-2021-052556

Article  Google Scholar 

Bogart, J. A., Waqar, S. N., & Mix, M. D. (2022). Radiation and systemic therapy for limited-stage small-cell lung cancer. Journal of Clinical Oncology, 40(6), 661–670. https://doi.org/10.1200/JCO.21.01639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rittberg, R., Leung, B., Al-Hashami, Z., et al. (2022). Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer. Frontiers in Oncology, 15(12), 1002385. https://doi.org/10.3389/fonc.2022.1002385

Article  Google Scholar 

Ferrarotto, R., Anderson, I., Medgyasszay, B., et al. (2021). Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. Cancer Medicine, 10(17), 5748–5756. https://doi.org/10.1002/cam4.4089

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kondo, R., Watanabe, S., Shoji, S., et al. (2018). A phase II study of irinotecan for patients with previously treated small-cell lung cancer. Oncology, 94, 223–232. https://doi.org/10.1159/000486622

Article  CAS  PubMed  Google Scholar 

Ahn, M. J., Cho, B. C., Felip, E., et al. (2023). Tarlatamab for patients with previously treated small cell lung cancer. New England Journal of Medicine, 389(22), 2063–2075. https://doi.org/10.1056/NEJMoa2307980

Article  CAS  PubMed  Google Scholar 

Chandana, S. R., Choudury, N. J., Dowlati, A., et al. (2004). First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. Journal Clinical Oncology, 42, 16. https://doi.org/10.1200/JCO.2024.42.16_suppl.300

Article  Google Scholar 

Oronsky, B., Takahashi, L., Gordon, R., Cabrales, P., Caroen, S., & Reid, T. (2023). RRx-001: A chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist. Frontiers in Oncology, 29(13), 1204143. https://doi.org/10.3389/fonc.2023.1204143

Article  CAS  Google Scholar 

Jayabalan, N., Oronsky, B., Cabrales, P., et al. (2023). A review of RRx-001: A late-stage multiindication inhibitor of NLRP3 activation and chronic inflammation. Drugs, 83(5), 389–402. https://doi.org/10.1007/s40265-023-01838-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao, H., Ning, S., Scicinski, J., Oronsky, B., Knox, S. J., & Peehl, D. M. (2015). Epigenetic effects of RRx001: A possible unifying mechanism of anticancer activity. Oncotarget, 6(41), 43172–43181. https://doi.org/10.18632/oncotarget.6526

Article  PubMed  PubMed Central  Google Scholar 

Morgensztern, D., Rose, M., Waqar, S. N., et al. (2019). RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. British Journal of Cancer, 121(3), 211–217. https://doi.org/10.1038/s41416-019-0504-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reid, T., Oronsky, B., Scicinski, J., et al. (2015). Safety and activity of RRx-001 in patients with advanced cancer: A first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol, 16(9), 1133–1142. https://doi.org/10.1016/S1470-2045(15)00089-3

Article  CAS  PubMed  Google Scholar 

Bonomi, M., Blakaj, D. M., Kabarriti, R., et al. (2023). PREVLAR: Phase 2 a randomized trial to assess the safety and efficacy of RRx-001 in the attenuation of oral mucositis in patients receiving head and neck chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics, 116(3), 551–559. https://doi.org/10.1016/j.ijrobp.2022.12.031

Article  Google Scholar 

Johnson M, Awad M, Koyama T, et al. (2023, November). Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: A subgroup analysis of a phase 1/2 study. In 2023 World Conference on Lung Cancer. OA05 antibody drug conjugates: The next tsunami, sunday, September 10, 2023 - 15:00 - 16:00| Vol. 18, Issue 11. Supplement, S54–S55.

Oronsky, B., Caroen, S., Oronsky, A., et al. (2017). Electrolyte disorders with platinum-based chemotherapy: Mechanisms, manifestations and management. Cancer Chemotherapy and Pharmacology, 80(5), 895–907. https://doi.org/10.1007/s00280-017-3392-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rottenberg, S., Disler, C., & Perego, P. (2021). The rediscovery of platinum-based cancer therapy. Nature Reviews Cancer, 21(1), 37–50. https://doi.org/10.1038/s41568-020-00308-y

Article  CAS  PubMed  Google Scholar 

Oronsky, B., Ray, C. M., Spira, A. I., Trepel, J. B., Carter, C. A., & Cottrill, H. M. (2017). A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Medical Oncology, 34(6), 103. https://doi.org/10.1007/s12032-017-0960-z

Article  CAS  PubMed  Google Scholar 

Herzog, B. H., Devarakonda, S., & Govindan, R. (2021). Overcoming chemotherapy resistance in SCLC. Journal of Thoracic Oncology, 16(12), 2002–2015. https://doi.org/10.1016/j.jtho.2021.07.018

Article  CAS  PubMed  Google Scholar 

Lissa, D., Takahashi, N., Desai, P., et al. (2022). Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models. Nature Communications, 13(1), 2023. https://doi.org/10.1038/s41467-022-29517-9

Article  CAS  PubMed  PubMed Central  Google Scholar